Beta Bionics, Inc. (BBNX) Price & Analysis

Compare

50 Followers

BBNX Stock Chart & Stats

$13.83

Market closed

$13.83

Day’s Range― - ―

52-Week Range$8.89 - $32.71

Previous CloseN/A

VolumeN/A

Average Volume (3M)917.05K

Market Cap

$608.86M

Enterprise Value$578.06M

Total Cash (Recent Filing)$228.69M

Total Debt (Recent Filing)$7.69M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Feb 17, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding44,024,630

10 Day Avg. Volume410,323

30 Day Avg. Volume917,055

Financial Highlights & Ratios

PEG Ratio-0.79

Price to Book (P/B)1.98

Price to Sales (P/S)2.31

P/FCF Ratio-2.91

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue6.53

Enterprise Value/Gross Profit11.97

Enterprise Value/Ebitda-8.84

Forecast

1Y Price Target

$28.71

Price Target Upside107.59% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Device Usability And AdoptionAnalyst highlights that the iLet system's ability to learn an individual's glucose patterns and reduce required patient interaction can attract patients and less-experienced prescribers, supporting adoption.

Patch Pump As A CatalystAnalyst expects the planned therapeutic patch pump to act as a catalyst for accelerating new patient starts and to support the long-term investment case when launched.

Product Differentiation And GrowthAnalyst notes that the company's differentiated insulin delivery system and expanding development pipeline should support revenue growth that outpaces peers.

Bears Say

New Patient Starts And TransparencyAnalyst notes that new patient starts came in below expectations and that stopping disclosure of specific start figures reduces transparency on the company's growth momentum.

Survey ReliabilityAnalyst warns that reliance on a small clinician survey sample creates substantial uncertainty around market share projections and weakens confidence in uptake estimates.

Valuation And ProfitabilityAnalyst highlights that the stock trades at a high valuation versus peers and that lack of profitability limits the potential for sustained upside without clearer paths to margin improvement.

Beta Bionics, Inc. News

Beta Bionics initiated with a Hold at TD Cowen

TD Cowen initiated coverage of Beta Bionics (BBNX) with a Hold rating and $17 price target The company’s...

6d ago

BBNX

Beta Bionics price target lowered to $25 from $33 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Beta Bionics (BBNX) to $25 from $33...

17d ago

BBNX

Midday Fly By: Job growth comes in below forecasts in December

The major averages were broadly higher near noon after the December nonfarm payrolls report. Stocks have shown resilience...

23d ago

Beta Bionics price target raised to $40 from $35 at Lake Street

Lake Street raised the firm’s price target on Beta Bionics (BBNX) to $40 from $35 and keeps a...

23d ago

BBNX

Beta Bionics downgraded to Neutral from Buy at BofA

BofA downgraded Beta Bionics (BBNX) to Neutral from Buy with a price target of $28, down from $33....

23d ago

BBNX

Beta Bionics sees Q4 revenue at least $32M, consensus $28.19M

Installed customer base is expected to be at least 35,000 users, up at least 128% compared to 15,298...

24d ago

BBNX

Beta Bionics price target raised to $33 from $30 at BofA

BofA analyst Travis Steed raised the firm’s price target on Beta Bionics (BBNX) to $33 from $30 and...

27d ago

BBNX

Beta Bionics Receives FDA Warning Letter, Begins Remediation

Beta Bionics, Inc. ( ($BBNX) ) has shared an announcement. On January 29, 2026, Beta Bionics, Inc. disclosed...

2d ago

BBNX

Balancing Growth Potential and Emerging Uncertainty: TD Cowen Maintains Hold on Beta Bionics with $17 Price Target

Beta Bionics, Inc. (BBNX) has received a new Hold rating, initiated by TD Cowen analyst, . TD Cowen...

6d ago

BBNX

Premium Valuation and Slowing New Patient Growth Drive Shift to Neutral on Beta Bionics

In a report released yesterday, Travis Steed from Bank of America Securities downgraded Beta Bionics, Inc. to a...

23d ago

BBNX

Beta Bionics price target raised to $37 from $32 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Beta Bionics (BBNX) to $37 from $32 and...

2M ago

BBNX

Beta Bionics price target raised to $28 from $23 at Baird

Baird raised the firm’s price target on Beta Bionics (BBNX) to $28 from $23 and keeps a Neutral...

2M ago

BBNX

Fourteen new option listings on November 12th

New option listings for November 12th include Direxion Daily AMD Bear 1X Shares (AMDD), Beta Bionics Inc (BBNX),...

3M ago

MST

PRE

Beta Bionics Reports Strong Q3 Growth Amid Challenges

Beta Bionics, Inc. (($BBNX)) has held its Q3 earnings call. Read on for the main highlights of the...

3M ago

BBNX

BBNX FAQ

What was Beta Bionics, Inc.’s price range in the past 12 months?

Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $32.71 in the past 12 months.

What is Beta Bionics, Inc.’s market cap?

Beta Bionics, Inc.’s market cap is $608.86M.

When is Beta Bionics, Inc.’s upcoming earnings report date?

Beta Bionics, Inc.’s upcoming earnings report date is Feb 17, 2026 which is in 16 days.

How were Beta Bionics, Inc.’s earnings last quarter?

Beta Bionics, Inc. released its earnings results on Oct 28, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.093.

Is Beta Bionics, Inc. overvalued?

According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Beta Bionics, Inc. pay dividends?

Beta Bionics, Inc. does not currently pay dividends.

What is Beta Bionics, Inc.’s EPS estimate?

Beta Bionics, Inc.’s EPS estimate is -0.4.

How many shares outstanding does Beta Bionics, Inc. have?

Beta Bionics, Inc. has 44,024,630 shares outstanding.

What happened to Beta Bionics, Inc.’s price movement after its last earnings report?

Beta Bionics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went up 10.338%.

Which hedge fund is a major shareholder of Beta Bionics, Inc.?

Currently, no hedge funds are holding shares in BBNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Beta Bionics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-47.52%

Trailing 12-Months

Asset Growth

35.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Beta Bionics, Inc. (BBNX) Earnings & Revenues

Historic Earnings Reports

BBNX Company Deck

BBNX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented several positive developments, including strong revenue growth, an increase in new patient starts, and an expanded presence in the pharmacy channel. However, there were concerns about increased operating expenses, a notable churn rate, and potential uncertainties from CMS proposals. Overall, the positive aspects outweigh the negative, reflecting a strong quarter and optimistic future guidance.View all BBNX earnings summaries

BBNX Stock 12 Month Forecast

Average Price Target

$28.71

▲(107.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","41":"$41","17.75":"$17.75","25.5":"$25.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,17.75,25.5,33.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,31.20307692307692,31.936153846153847,32.669230769230765,33.402307692307694,34.135384615384616,34.86846153846154,35.60153846153846,36.33461538461538,37.067692307692305,37.800769230769234,38.533846153846156,39.26692307692308,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,30.334615384615383,30.19923076923077,30.063846153846153,29.928461538461537,29.793076923076924,29.657692307692308,29.52230769230769,29.386923076923075,29.251538461538463,29.116153846153846,28.98076923076923,28.845384615384617,{"y":28.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,29.433846153846154,28.397692307692306,27.361538461538462,26.325384615384614,25.28923076923077,24.253076923076925,23.216923076923077,22.18076923076923,21.144615384615385,20.10846153846154,19.072307692307692,18.036153846153848,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.81,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >